Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases.

Continuous hepatic artery floxuridine infusion benefits patients with colorectal liver metastases. Implanted infusion pumps are more expensive but may result in fewer treatment interruptions than when using an external pump connected to a port. We have assessed device-related complications, treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Fordy, C., Burke, D., Earlam, S., Twort, P., Allen-Mersh, T. G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034031/
https://www.ncbi.nlm.nih.gov/pubmed/7547216
_version_ 1782136967903838208
author Fordy, C.
Burke, D.
Earlam, S.
Twort, P.
Allen-Mersh, T. G.
author_facet Fordy, C.
Burke, D.
Earlam, S.
Twort, P.
Allen-Mersh, T. G.
author_sort Fordy, C.
collection PubMed
description Continuous hepatic artery floxuridine infusion benefits patients with colorectal liver metastases. Implanted infusion pumps are more expensive but may result in fewer treatment interruptions than when using an external pump connected to a port. We have assessed device-related complications, treatment interruptions and added nurse interventions in 95 patients undergoing a total of 959 treatment cycles via either implanted pump (64 patients) or port (31 patients). Compared with the implanted pump, the port was associated with a significant increase (P < 0.003) in catheter blockage (24/31 vs 2/64 patients), treatment interruption (15/265 vs 12/694 treatments) and added nurse intervention (80/265 vs 20/694 treatments). Survival in patients with colorectal liver metastases is limited and the complications of treatment should be kept to a minimum. An implanted subcutaneous infusion pump offers the benefit of a 3-fold lower incidence of treatment interruption and a 30-fold lower incidence of catheter blockage than when continuous infusion chemotherapy is given via an external infusion device. IMAGES:
format Text
id pubmed-2034031
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20340312009-09-10 Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases. Fordy, C. Burke, D. Earlam, S. Twort, P. Allen-Mersh, T. G. Br J Cancer Research Article Continuous hepatic artery floxuridine infusion benefits patients with colorectal liver metastases. Implanted infusion pumps are more expensive but may result in fewer treatment interruptions than when using an external pump connected to a port. We have assessed device-related complications, treatment interruptions and added nurse interventions in 95 patients undergoing a total of 959 treatment cycles via either implanted pump (64 patients) or port (31 patients). Compared with the implanted pump, the port was associated with a significant increase (P < 0.003) in catheter blockage (24/31 vs 2/64 patients), treatment interruption (15/265 vs 12/694 treatments) and added nurse intervention (80/265 vs 20/694 treatments). Survival in patients with colorectal liver metastases is limited and the complications of treatment should be kept to a minimum. An implanted subcutaneous infusion pump offers the benefit of a 3-fold lower incidence of treatment interruption and a 30-fold lower incidence of catheter blockage than when continuous infusion chemotherapy is given via an external infusion device. IMAGES: Nature Publishing Group 1995-10 /pmc/articles/PMC2034031/ /pubmed/7547216 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Fordy, C.
Burke, D.
Earlam, S.
Twort, P.
Allen-Mersh, T. G.
Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases.
title Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases.
title_full Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases.
title_fullStr Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases.
title_full_unstemmed Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases.
title_short Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases.
title_sort treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034031/
https://www.ncbi.nlm.nih.gov/pubmed/7547216
work_keys_str_mv AT fordyc treatmentinterruptionsandcomplicationswithtwocontinuoushepaticarteryfloxuridineinfusionsystemsincolorectallivermetastases
AT burked treatmentinterruptionsandcomplicationswithtwocontinuoushepaticarteryfloxuridineinfusionsystemsincolorectallivermetastases
AT earlams treatmentinterruptionsandcomplicationswithtwocontinuoushepaticarteryfloxuridineinfusionsystemsincolorectallivermetastases
AT twortp treatmentinterruptionsandcomplicationswithtwocontinuoushepaticarteryfloxuridineinfusionsystemsincolorectallivermetastases
AT allenmershtg treatmentinterruptionsandcomplicationswithtwocontinuoushepaticarteryfloxuridineinfusionsystemsincolorectallivermetastases

Ejemplares similares